Person: ESER, ALİ
Now showing 1 - 4 of 4
Publication Open AccessThe Efficacy of Eltrombopag Treatment in Patients who developed Platelet Engraftment Failure after Allogeneic Stem Cell Transplantation: A Single Center Experience(2021-03-01T00:00:00Z) ESER, ALİ; Timuragaoglu, Aysen; ESER, ALİObjective: Persistent thrombocytopenia is a common complication of allogeneic stem cell transplantation (ASCT). Treatment of platelet engraftment failure after ASCT remains controversial. Drugs, such as eltrombopag, are used for this purpose. Eltrombopag is an Food and Drug Administration -approved oral thrombopoietin receptor agonist. We aim to present the results of 12 patients treated with eltrombopag in our center for severe thrombocytopenia after ASCT. Methods: From January 2018 to February 2020, a total of 56 patients underwent ASCT. Twelve patients had persistent thrombocytopenia following ASCT All patients received eltrombopag. Results: Primary platelet engraftment failure developed in six of 12 patients who developed persistent thrombocytopenia after ASCT. Secondary platelet engraftment failure developed in six of them. After eltrombopag treatment, eight (66.7%) patients achieved transfusion independence, whereas four patients (33.3%) could not. The maximum platelet count after the eltrombopag treatment was median 118.000 (range: 24,000-253,000)/mu L. The median time from the start of eltmmbopag until the platelet count was >50,000/mu L was 18 (range: 14-112) days. The median duration of treatment with eltrombopag was 70 (range: 26-180) days. Eltrombopag was discontinued in all patients who survived and had full platelet recovery. Conclusion: Thrombocytopcnia after ASCT is a condition that should be treated as it can lead to life-threatening bleeding. Publication Metadata onlyMETABOLIC SYNDROME IN COLLECTION AND DISPOSAL OF SOLID WASTE SECTOR(2012-01-01T00:00:00Z) Eker, Hasan Huseyin; BAYRAKTARLI, Recep Yilmaz; Issever, Halim; Ulas, Tumer; Erelel, Mustafa; ESER, ALİ; OZDILLI, Kursat; Ozder, ACLAN; ESER, ALİ; ÖZDER, ACLANObjectives: This study aims to assess the frequency and factors relevant to metabolic syndrome in workers employed in the collection and disposal of solid waste sector. Materials and Methods: This cross-sectional study was conducted in the major solid waste collecting and disposal company named ISTAC AS (Istanbul Environmental Protection and Waste Processing Corporation) in Istanbul, Turkey. All 715 male employees of the company were included in the study without sampling. The study was completed with 619 subjects. Since it was a small group, female workers were not taken into account in the study. Metabolic syndrome frequency was investigated according to the NCEP-ATP III criteria including the levels of systolic and diastolic blood pressure, waist perimeter, HDL, triglyceride, fasting blood glucose values. Results: Metabolic syndrome was present in 40.9% of participating employees. Metabolic syndrome was more common in those working in the excavation field (54.0%), such as caterpillar operators (56.5%), and less common in employees working in administrative offices, such as office staff or managers, who were under 35 years old and who had been working for less than 10 years (p < 0.05). Employees working in work stations other than administrative offices had a 2.60 times higher risk compared to those working in administrative offices. Conclusions: Metabolic syndrome may be related to work station, job, age and period worked by the subjects. Publication Open AccessThe Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: -A Single-Center Experience-(2021-05-01T00:00:00Z) ESER, ALİ; Timuragaoglu, Aysen; ESER, ALİIntroduction: High-dose chemotherapy fol lowed by autologous stem cell transplantation (ASCT) is the standard treatment for relapsed and refractory lymphoma patients. The difficulties in accessing and high cost of carmustine have led to the increased use of alternative regimen before ASCT for the treatment of lymphoma, including busulfan-based busulfan-etoposidemelphalan (BuEM) regimens. Publication Open AccessIndefinite Azacitidine Treatment Until Progression May Provide Long-Term Disease Control in Elderly Patients with Acute Myelogenous Leukemia(2018-07-01T00:00:00Z) ESER, Ali; Sezgin, Aslihan; Kara, Osman; BOZKURT, SÜHEYLA; ESER, ALİThe prognosis of acute myelogenous leukemia (AML) is poor in elderly patients. The mean survival rates at second and fifth years for AML were 10% and 2%, respectively. Here our aim was to demonstrate that the survival rate can be prolonged by long-term azacitidine (AZA) treatment. Complete remission was achieved at the end of the fourth and sixth courses of AZA treatment in three elderly patients with AML with a high blast count. The first patient was followed without any treatment after getting complete remission with four courses of AZA, and at the end of 1 year follow-up, the patient died due to pneumonia. Complete remission was obtained in the second and third patients after four and six courses of AZA, respectively. Second patient is still being followed up in complete remission at the end of the 20th course of AZA. Recurrence occurred at the end of the 16th AZA course in the third patient and he died after 20 months of the treatment. In elderly patients with AML with a high blast count, the continuation of AZA treatment improves the overall survival rates.